BA
TEVA icon

Bridgewater Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Bridgewater Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34M Buy
1,128,406
+374,313
+50% +$12M 0.15% 100
2025
Q4 		$23.5M Sell
754,093
-110,689
-13% -$2.73M 0.09% 173
2025
Q3 		$17.5M Buy
+864,782
New +$15.2M 0.07% 228
2025
Q1 		– Sell
-9,393
Closed -$207K – 790
2024
Q4 		$207K Sell
9,393
-13,829
-60% -$252K ﹤0.01% 677
2024
Q3 		$418K Buy
23,222
+1,144
+5% +$20K ﹤0.01% 705
2024
Q2 		$359K Sell
22,078
-24,583
-53% -$379K ﹤0.01% 799
2024
Q1 		$658K Sell
46,661
-26,413
-36% -$333K ﹤0.01% 602
2023
Q4 		$763K Sell
73,074
-121,451
-62% -$1.13M ﹤0.01% 667
2023
Q3 		$1.98M Sell
194,525
-37,985
-16% -$354K 0.01% 502
2023
Q2 		$1.75M Sell
232,510
-10,137
-4% -$82.2K 0.01% 488
2023
Q1 		$2.15M Sell
242,647
-66,770
-22% -$660K 0.01% 451
2022
Q4 		$2.82M Sell
309,417
-134,841
-30% -$1.18M 0.02% 470
2022
Q3 		$3.58M Sell
444,258
-40,785
-8% -$361K 0.02% 450
2022
Q2 		$3.65M Sell
485,043
-56,471
-10% -$492K 0.02% 569
2022
Q1 		$5.08M Buy
541,514
+21,895
+4% +$183K 0.02% 465
2021
Q4 		$4.16M Buy
519,619
+244,402
+89% +$2.21M 0.02% 335
2021
Q3 		$2.68M Buy
275,217
+33,548
+14% +$314K 0.01% 390
2021
Q2 		$2.39M Buy
+241,669
New +$2.56M 0.02% 461
2018
Q4 		– Sell
-23,600
Closed -$508K – 513
2018
Q3 		$508K Buy
23,600
+2,400
+11% +$55.7K 0.01% 279
2018
Q2 		$516K Hold
21,200
– – 0.01% 360
2018
Q1 		$362K Sell
21,200
-6,500
-23% -$127K ﹤0.01% 415
2017
Q4 		$525K Hold
27,700
– – ﹤0.01% 224
2017
Q3 		$488K Hold
27,700
– – ﹤0.01% 255
2017
Q2 		$920K Buy
27,700
+3,000
+12% +$92.9K 0.01% 214
2017
Q1 		$793K Hold
24,700
– – 0.01% 202
2016
Q4 		$895K Hold
24,700
– – 0.01% 233
2016
Q3 		$1.14M Hold
24,700
– – 0.01% 217
2016
Q2 		$1.24M Hold
24,700
– – 0.02% 226
2016
Q1 		$1.32M Buy
24,700
+600
+2% +$35.2K 0.02% 210
2015
Q4 		$1.58M Buy
+24,100
New +$1.49M 0.02% 199

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgewater Associates's TEVA Position: Q1 2026 in Review

Bridgewater Associates increased its Teva Pharmaceuticals (TEVA) stake by 50% in Q1 2026, buying an estimated $12M and bringing the position to 1,128,406 shares worth $34M. The position accounts for 0.15% of the portfolio, ranked #100.

Bridgewater Associates first reported a position in TEVA in Q4 2015 and has held it in 30 quarters since. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Bridgewater Associates held 1,128,406 shares of Teva Pharmaceuticals worth $34M as of Q1 2026.
  • Bridgewater Associates bought 374,313 Teva Pharmaceuticals shares in Q1 2026, an estimated $12M.
  • Teva Pharmaceuticals made up 0.15% of Bridgewater Associates's portfolio in Q1 2026, its #100 holding.
  • Bridgewater Associates first reported a position in Teva Pharmaceuticals in Q4 2015 and has held it in 30 quarters since.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.